Eliquis (Atrial Fibrillation) - Analysis and Forecasts to 2022

NEW YORK, June 14, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Eliquis (Atrial Fibrillation) – Analysis and Forecasts to 2022

http://www.reportlinker.com/p0886901/Eliquis-Atrial-Fibrillation-–-Analysis-and-Forecasts-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory

Eliquis (Atrial Fibrillation) – Analysis and Forecasts to 2022

Summary

GlobalData's pharmaceuticals report, "Eliquis (Atrial Fibrillation) – Analysis and Forecasts to 2022" provides Eliquis global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2012-2022). The report also includes information on Atrial Fibrillation market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)

- Analysis and review of Eliquis including sales data

- Qualitative and quantitative assessment of market space

- Analysis of the trends, drivers and restraints shaping and defining the markets

- In-depth analysis of Eliquis including efficacy, safety, pricing, competition and other details which influence its sales potential

- Global sales forecast for 2012-2022 for Eliquis

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of competition by understanding the changing competitive landscape

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of the drug's performance

- Examine the historical sales performance of a drug in seven major markets

- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 3

1.2 List of Figures 4

2 Introduction 5

2.1 Atrial Fibrillation Market 5

2.2 Epidemiology 5

2.3 Etiology and Risk Factors 6

2.3.1 Symptoms associated with AF 7

2.4 GlobalData Analysis and Forecasts Report Guidance 8

3 Atrial Fibrillation: Market Characterization 9

3.1 Atrial Fibrillation Market 9

3.2 Atrial Fibrillation Market Forecasts and CAGR 10

3.3 Drivers of Atrial Fibrillation Market 10

3.3.1 High Unmet need 10

3.3.2 Strong Pipeline 11

3.3.3 Increase in prevalence and ageing populations 11

3.3.4 Organisation of Awareness Campaigns 12

3.4 Barriers in Atrial Fibrillation Market 13

3.4.1 Limitations in established therapies 13

3.4.2 High cost of emerging therapies 13

4 Classification in Atrial Fibrillation: Introduction 14

4.1 AF Classification 14

4.1.1 Pathophysiology of AF 15

4.1.2 Diagnosis in Atrial Fibrillation 16

4.1.3 Impact of Atrial Fibrillation 17

5 Treatment Options and Management in Atrial Fibrillation 18

5.1 Rate control and Rhythm control 18

5.2 Rate Control Versus Rhythm Control 20

6 Eliquis 21

6.1 Introduction 21

6.2 Mechanism of Action 21

6.3 Clinical Studies 21

6.4 Approval History 21

6.5 Factors Affecting Sales of Eliquis 22

6.5.1 Superior Efficacy and Safety Profile 22

6.5.2 Speedy action to Warfarin 22

6.5.3 Early entry into the market 22

6.5.4 Superior bleeding profile among competitors 22

6.6 Drug Evaluation 22

6.6.1 Drug Risk Benefit Score 22

6.6.2 Intensity of Competition 23

6.7 Sales Forecast 24

6.7.1 Target Patient Pool of Eliquis 24

6.7.2 Dosing 24

6.7.3 Market Penetration 24

6.7.4 Annual Cost of Therapy 25

6.7.5 Global Sales Projections of Eliquis 26

7 Appendix 35

7.1 Market Definitions 35

7.2 Abbreviations 35

7.3 Research Methodology 35

7.3.1 Coverage 35

7.3.2 Secondary Research 36

7.3.3 Forecasting 36

7.3.4 Number of Patients Approved to Take the Drug 36

7.3.5 Net Penetration of Drug 37

7.3.6 Net Annual Dosing 37

7.3.7 Annual Cost of Therapy 37

7.4 Drug Sales Estimates Model 37

7.5 Contact Us 37

7.6 Disclaimer 38

7.7 Sources 38

List of Tables

Table 1: Epidemiology of Atrial Fibrillation (2011) 6

Table 2: Increase in the Risk of AF in The Presence of Risk Factors 6

Table 3: Stratification of All Risk Factors For Atrial Fibrillation 7

Table 4: Atrial Fibrillation Classification 15

Table 5: Treatment Guidelines For the Management of Atrial Fibrillation 18

Table 6: Drug Risk Benefit Score of Eliquis 23

Table 7: Eliquis, Atrial Fibrillation, Global, Annual Cost of Therapy ($), 2011 25

Table 8: Eliquis, Atrial Fibrillation, Global, Sales Forecasts ($m), 2012–2022 26

Table 9: Eliquis, Atrial Fibrillation, The US, Sales Forecasts ($m), 2012–2022 27

Table 10: Eliquis, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2012–2022 28

Table 11: Eliquis, Atrial Fibrillation, France, Sales Forecasts ($m), 2012–2022 29

Table 12: Eliquis, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2012–2022 30

Table 13: Eliquis, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2012–2022 31

Table 14: Eliquis, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2012–2022 32

Table 15: Eliquis, Atrial Fibrillation, Japan, Sales Forecasts ($m), 2012–2022 33

List of Figures

Figure 1: Atrial Fibrillation, Global, Market Size Forecasts ($bn), 2011–2022 10

Figure 2: Percentage Of Molecules (in Different Phases of Development) For Atrial Fibrillation 11

Figure 3: Increase of Prevalance Population in Atrial Fibrillation 12

Figure 4: Normal Heart Rhythm Vs Atrial Fibrillation 14

Figure 5: Broad classification of Patterns in Atrial Fibrillation 15

Figure 6: Disease States Associated with Atrial Fibrillation, By (%) 16

Figure 7: Therapeutic Goals in Patients with Atrial Fibrillation (AF) 19

Figure 8: Management of Newly Discovered Atrial Fibrillation (AF) 19

Figure 9: Drug Model Diagram of Eliquis 24

Figure 10: Eliquis, Atrial Fibrillation, Global, Sales Forecasts ($m), 2012–2022 26

Figure 11: Eliquis, Atrial Fibrillation, The US, Sales Forecasts ($m), 2012–2022 27

Figure 12: Eliquis, Atrial Fibrillation, The UK, Sales Forecasts ($m), 2012–2022 28

Figure 13: Eliquis, Atrial Fibrillation, France, Sales Forecasts ($m), 2012–2022 29

Figure 14: Eliquis, Atrial Fibrillation, Germany, Sales Forecasts ($m), 2012–2022 30

Figure 15: Eliquis, Atrial Fibrillation, Italy, Sales Forecasts ($m), 2012–2022 31

Figure 16: Eliquis, Atrial Fibrillation, Spain, Sales Forecasts ($m), 2012–2022 32

Figure 17: Eliquis, Atrial Fibrillation, Japan, Sales Forecasts ($m), 2012–2022 33

Figure 18: Eliquis, Atrial Fibrillation, Global, Sales Distribution, By Country (%), 2022 34

Figure 19: Patients Approved for the Drug 36

To order this report:

: Eliquis (Atrial Fibrillation) – Analysis and Forecasts to 2022

Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker